MINNEAPOLIS, Oct. 04, 2016 -- On September 16, 2016, Vascular Solutions, Inc. (Nasdaq:VASC), initiated a nationwide recall of Twin-Pass Dual Access catheters used in catheterization procedures. All unexpired lots of the product have been recalled because there is a potential for excess manufacturing material to remain at the tip of the catheter or within the distal portion of the rapid exchange lumen. It is possible that the excess material may separate from the catheter during use and pose a potential risk of embolism, which could result in serious injury or death. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Twin-Pass dual access catheters should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from October 2014 to August 2016 and distributed from October 2014 to September 2016.
The recalled products are all unexpired lots of Model Numbers 5200, 5210, and 5230. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 15,896 devices have been manufactured, with 5,784 distributed in the United States and currently unexpired. The condition that led to the recall may affect approximately 9.2% of recalled devices.
Vascular Solutions, Inc. voluntarily initiated the recall on September 16, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific unexpired lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company has launched more than 100 products that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 



